With more than three decades of executive experience creating and developing successful medical and pharmaceutical service business ventures, Dr. Vanscoy is a recognized leader in the health care industry and a pioneer in the specialty pharmacy (SP) sector. He is the founding Chairman and CEO of PANTHERx Specialty Pharmacy, The Rare Disease SP®, and RareMed® Solutions. PANTHERx is a quad-accredited SP recognized by INC Magazine as the fastest growing healthcare company, and by Modern Healthcare as one of the top 10 best places to work in the nation. In addition, PANTHERx Specialty Pharmacy has received back-to-back annual Zitter Health Insights Patient Satisfaction Award, receiving the highest score ever attained on a quarterly survey. Gordon also serves as the Associate Dean for Business Innovation and Associate Professor of Pharmacy and Therapeutics at the University of Pittsburgh (Pitt), where he recently launched the Master of Science in Pharmacy Business Administration degree program.
Prior to founding PANTHERx, Dr. Vanscoy served as the Chairman and CEO of WellCo Medical Solutions Inc., GreenCare US, LLC, and University Pharmacotherapy Associates Inc. Earlier in his career, while serving as Assistant Dean for Managed Care at Pitt, Gordon helped to grow one of the country’s first specialty pharmacy’s, Stadtlanders. He rose as an executive with Bergen Brunswig Specialty, and became Executive Vice President and Chief Operating Officer at CVS ProCare. Prior to specialty pharmacy, Gordon served as Vice-Chair of the Department of Pharmacy and Therapeutics where he founded UPMC’s Drug Information and Pharmacoepidemiology Center. He was an active member of the University Biomedical Institutional Review Board, serving as Vice Chairman. At the beginning of his career, he developed one of the country’s first Anticoagulation Clinic Services and obtained medication-prescribing privileges at the Pittsburgh Veterans Affairs Health System.
Dr. Vanscoy’s primary research interest is the pharmacoeconomic modeling of high-risk, high-cost disease states while his scholarly focus is on advancing education in the business of medicines to create future leaders. He received his Bachelors of Science in Pharmacy and Masters of Business Administration degrees from the University of Pittsburgh, and his Doctor of Pharmacy degree from Duquesne University. Gordon completed an American Society of Health System Pharmacists (ASHP)-accredited clinical residency at The Mercy Hospital of Pittsburgh and a faculty fellowship in advanced geriatrics at the University of Pittsburgh Geriatric Education Center. He is nationally credentialed as a Certified Anticoagulation Care Provider.
In 2017, Dr. Vanscoy was awarded the University of Pittsburgh's highest recognition, the Distinguished Alumni Fellow Award. In 2017, the Pittsburgh Business Times acknowledged him with a Pittsburgh Outstanding CEO and Top Executive Award. Gordon was recognized in 2016 by Smart Business Magazine as the top executive of one of the 50 smartest companies in the Western Pennsylvania for his ability to effectively build and lead successful organizations. He has published a number of textbook chapters, hundreds of scientific papers, and has received dozens of research grants and awards. Dr. Vanscoy has provided nearly a thousand invited lectures and served on many national and international committees. He is a past board member of the International Society of Pharmaceutical Outcomes (ISPOR), the ACPE National CE Provider Committee, the United States Pharmacopoeia’s (USP) Therapeutic Information Management Advisory Panel, the National Certified Anticoagulation Care Providers (CACP), the ASHP Foundation, and the American Red Cross. Gordon currently serves on the Board of Directors of the National Association of Specialty Pharmacy.
His primary research interests include economic modeling of high-risk, high-cost disease states related to oncology, cardiology, critical care, and anticoagulation. His scholarly focus is on advancing education in entrepreneurship and the business of medicines to create future leaders.